CHICAGO – After gaining approval in January for Trulance (plecanatide) to treat chronic idiopathic constipation (CIC), Synergy Pharmaceuticals Inc. wasted little time posting the complete phase III dataset on a bigger win sought in irritable bowel syndrome with constipation (IBS-C).